European adaptive randomised controlled trial to improve survival in ICU-admitted patients with Severe Community Acquired Pneumonia (sCAP).
REMAP-CAP: Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia
This is a perpetual European adaptive RCT evaluating the effectiveness of several interventions in increasing the number of ventilator and vasopressor free days(day-60) and reducing day-60 mortality in adult patients admitted to ICU with sCAP. We will use CAP as disease definition, because the patients with disease represent most of morbidity and mortality caused by SARI in the developed world. Each intervention will be compared to standard care using a Bayesian approach for statistical analysis. The study will be performed in adult intensive care units (ICU) and will have 2,000-4,000 patients enrolled in 100 – 150 ICU across Europe. The targeted patient population are adults, highly suspected of CAP (at least two clinical signs and symptoms and radiological confirmation), requiring invasive mechanical ventilation within the first 48h after presentation to the hospital and are subsequently admitted to ICU.
Login as a member to see more information.